| ￥3300 | |
| Z05852-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized SOST/Sclerostin, His & Avi, Human at 0.5μg/ml (100μl/Well) on the plate can bind AntiSOST Antibody, hFc Tag. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 24.2 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation,the protein migrates to 28-40 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | SOST, also known as sclerostin, is a member of the cerberus/DAN family, a group of secreted glycoproteins characterized by a cysteine-knot motif. SOST is negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation. |
| Synonyms | sclerostin; SOST; VBCHsclerosteosis; CDD; DAND6; SOST1; VBCH |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
